JNJ-64300535 + nucleos(t)ide analogs

Combination therapy consisting of **JNJ-64300535 (also known as JNJ-0535)**, a DNA vaccine with two plasmids encoding hepatitis B virus (HBV) core and polymerase proteins, and **nucleos(t)ide analogs**, a standard class of oral antiviral agents for chronic hepatitis B infection. JNJ-64300535 is administered intramuscularly via electroporation to enhance cellular uptake, aiming to induce HBV-specific T cell responses. Nucleos(t)ide analogs suppress HBV replication and reduce viral load. The combination is under investigation for its ability to boost immune control over HBV and potentially enable treatment withdrawal without viral rebound. The combination is developed primarily for patients with chronic hepatitis B who are virologically suppressed on long-term nucleos(t)ide analog therapy[1][2][3][5][7].